European Commission Clears Amgen IMDYLLTRA for ES-SCLC, Cuts Death Risk 40%
AMGN•European Commission approves Amgen’s IMDYLLTRA for adults with extensive-stage small cell lung cancer after progression on platinum-based chemotherapy. Phase 3 DeLLphi-304 trial showed a 40% reduction in death risk (HR 0.60) and extended median overall survival to 13.6 months versus 8.3 months.
1. EU Approval Overview
European Commission grants marketing authorization for IMDYLLTRA as monotherapy in adult patients with extensive-stage small cell lung cancer who have progressed following platinum-based chemotherapy. This decision positions IMDYLLTRA as the first T-cell engager approved for this indication in Europe.
2. Phase 3 DeLLphi-304 Efficacy
The approval is supported by Phase 3 DeLLphi-304 data demonstrating a 40% reduction in risk of death (hazard ratio 0.60; 95% CI 0.47–0.77; P<0.001) and an increase in median overall survival to 13.6 months versus 8.3 months with standard chemotherapy.
3. Safety and Monitoring
The safety profile of IMDYLLTRA reflects known risks, with cytokine release syndrome reported in 56.7% of patients (19.7% serious), along with decreased appetite, pyrexia, dysgeusia, anemia and neutropenia. Infusions require intensive monitoring for 6–8 hours during the first dosing cycles to manage adverse reactions.
4. Commercial and Clinical Next Steps
Amgen plans a phased launch throughout European markets, while ongoing DeLLphi trials explore IMDYLLTRA in earlier SCLC settings and combination regimens. Sales forecasts and reimbursement negotiations will shape its commercial uptake across member states.
